key: cord-0727594-irut5ki3 authors: Biancofiore, Annalucia; Mirijello, Antonio; Puteo, Maria A.; Di Viesti, Maria P.; Labonia, Maria; Copetti, Massimiliano; De Cosmo, Salvatore; Lombardi, Renato title: Remdesivir significantly reduces SARS‐CoV‐2 viral load on nasopharyngeal swabs in hospitalized patients with COVID‐19: A retrospective case–control study date: 2022-01-28 journal: J Med Virol DOI: 10.1002/jmv.27598 sha: 45dbae8bb76f2f77432899cc96bd9da129958750 doc_id: 727594 cord_uid: irut5ki3 Remdesivir is a broad‐spectrum antiviral agent able to inhibit the RNA polymerase of SARS‐CoV‐2. At present, studies focusing on the effect of remdesivir on viral load (VL) are few and with contrasting results. Aim of the present study was to evaluate the effect of remdesivir on SARS‐CoV‐2 VL from nasopharyngeal swabs (cycle threshold criterion) in a sample of patients treated with the drug, compared with patients who did not receive the antiviral treatment. This retrospective analysis evaluated patients with (1) real‐time polymerase chain reaction (RT‐PCR) confirmed COVID‐19 diagnosis and (2) availability of at least two positive nasopharyngeal swabs analysed with the same analytic platform (ORF target gene, Ingenius ELITe, ELITechGroup, Puteaux, France). Upper respiratory specimens from nasopharyngeal swabs were collected at admission (T0) and 7–14 days after treatment, upon clinical decision. A total of 27 patients treated with remdesivir (Group A) met the inclusion criteria and were compared with 18 patients (Group B) treated with standard care, matched for baseline clinical characteristics. At baseline, both remdesivir‐treated and nontreated patients showed comparable VLs (21.73 ± 6.81 vs. 19.27 ± 5.24, p = 0.348). At the second swab, remdesivir‐treated patients showed a steeper VL reduction with respect to controls (34.28 ± 7.73 vs. 27.22 ± 3.92; p < 0.001). Longitudinal linear model estimated a mean decrease in cycle threshold equal to 0.61 (SE: 0.09) per day in remdesivir‐treated versus 0.33 (SE: 0.10) per day in remdesivir nontreated patients (p for heterogeneity = 0.045). The present study shows that the administration of remdesivir in hospitalized COVID‐19 patients significantly reduces the VL on nasopharyngeal swabs. Coronavirus disease-2019 is characterized by an early viremic phase (e.g., presymptomatic and flu-like symptoms), followed by an inflammatory phase (e.g., fever, dyspnea, and hypoxemia) and a final stage characterized by complications (respiratory failure, multiorgan failure, and death). 1 Remdesivir is a broad-spectrum antiviral agent able to inhibit the RNA polymerase of several viruses including coronaviruses, ebola and hepatitis C virus. 2 Given its possible effect in reducing the severity and progression of disease, remdesivir has received an emergency approval for the treatment of COVID-19. [3] [4] [5] [6] Although remdesivir shows a significant in vitro activity in terms of reduction of viral load (VL) from respiratory specimens, 7 its effectiveness on clinical outcomes is still matter of debate. 8 In addition, evidences on the correlation between VL and clinical severity are controversial, [9] [10] [11] even if it has been shown that patients with more severe disease could present with a slower VL clearance. 7 At present, studies focusing on the effect of remdesivir on VL are few and with contrasting results. 9, 12, 13 The aim of the present study was to evaluate the effect of remdesivir on SARS-CoV-2 VL from nasopharyngeal swabs in a sample of patients treated with the drug, compared with patients who did not receive the antiviral treatment. For the present study we selected those patients who had at least two positive swabs confirmed by one of the seven available platforms, using the ORF target gene (Ingenius ELITe, ELITechGroup, Puteaux, France). The CT is defined as the number of amplification cycles required for the viral RNA signal to be detected by the analyser system. It represents a reliable, semi-quantitative, indicator of the presence viral genetic material inversely correlated to VL. 10 The cut-off value of CT was 35 (e.g., Demographic and clinical baseline patients' characteristics were reported as mean and SD or frequency and percentage for continuous and categorical variables, respectively. Group comparisons (remdesivir treated vs. nontreated) were carried out using Mann-Whitney U-test for continuous variables and Pearson chisquared test for categorical variables. Patients' VL measured at baseline and at a variable follow-up was analysed using a longitudinal linear model for repeated measurement with a spatial power covariance matrix, the last accounts for unequally spaced follow-up times. A p < 0.05 was considered as statistically significant. Table 1 shows baseline characteristics of patients, both as overall sample, and as comparison between groups. As expected, groups were comparable, excepted for the use of antibiotics (higher in Group B), corticosteroids and oxygen supplementation (higher in Group A). Moreover, the follow-up period (time from 1st to 2nd swab) was similar (14.81 ± 9.52 vs. 17.83 ± 9.84 days, p = 0.10). At baseline, both remdesivir-treated and nontreated patients showed comparable VLs in the study, including statistical reports and tables, and can take re- Remdesivir for early COVID-19 treatment of high-risk individuals prior to or at early disease onsetlessons learned Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 Remdesivir for the treatment of Covid-19-final report New perspectives on antimicrobial agents: remdesivir treatment for COVID-19 Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Systematic review and patientlevel meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies Repurposed antiviral drugs for Covid-19-Interim WHO Solidarity Trial Results Clinical and virologic effectiveness of remdesivir treatment for severe coronavirus disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study Viral load and disease severity in COVID-19 SARS-CoV-2 viral load is associated with increased disease severity and mortality A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel Viral load kinetics of severe acute respiratory syndrome coronavirus 2 in hospitalized individuals with coronavirus disease 2019 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Case report study of the first five COVID-19 patients treated with remdesivir in France Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with COVID-19 Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial Dexamethasone for COVID-19? Not so fast Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study Low eGFR is a strong predictor of worse outcome in hospitalized COVID-19 patients High-dose steroids for the treatment of severe COVID-19 Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: a retrospective case-control study